Introduction to HER2-Directed Tumor-Agnostic Approaches

Opinion
Video

Introduction to HER2-Directed Tumor-Agnostic Approaches

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
5 experts are featured in this series
Related Content
Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

OST-HER2 Yields Significant Survival in Pulmonary Metastatic Osteosarcoma

Russ Conroy
August 19th 2025
Article
1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
August 19th 2025
Podcast
Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

3 Things You Should Know About Evolving Strategies in SCLC: Limited-Stage Advances, Frontline Innovation, and Postplatinum Progress

ONCOLOGY Staff
August 19th 2025
Article
1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
August 19th 2025
Podcast
The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
August 19th 2025
Article
A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Roman Fabbricatore
August 19th 2025
Article